UroGen Pharma Ltd.

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to the development and commercialization of innovative treatments for urothelial and specialty cancers. The company's core focus lies in addressing unmet needs within the urology space, particularly for non-muscle invasive urothelial cancers. UroGen's proprietary RTGel technology serves as a foundational platform, enabling the development of novel drug delivery systems. Their lead product, Jelmyto, is a pyelocalyceal solution designed for the treatment of specific urothelial cancers. The company's pipeline includes promising candidates such as UGN-102, UGN-103, and UGN-104, which are in various stages of clinical development for both upper tract urothelial cancer and non-muscle invasive bladder cancer. UroGen is also exploring treatments for high-grade non-muscle invasive bladder cancer with candidates like UGN-301. Strategic collaborations are a key aspect of UroGen's business model, evidenced by their license agreements with Agenus Inc. for intravesical delivery of cancer treatments and with medac Gesellschaft für klinische Spezialpräparate m.b.H. for the development of specific pipeline assets. This approach allows UroGen to leverage external innovation while focusing on its core expertise in urologic oncology.